James Shannon The management shake-up at Novartis continues. The latest casualty is James Shannon, head of global drug development, who will be succeeded by two Novartis executives, the WSJ’s Jeanne Whalen reports.
Novartis has been reorganizing its pharmaceutical division after regulatory setbacks–including the withdrawal of constipation drug Zelnorm and a delay in FDA approval for diabetes pill [...]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment